The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. InventisBio Co., Limited 益方生物科技(上海)股份有限公司 (the "Company") (A joint stock company incorporated in the People's Republic of China with limited liabi ...

Core Insights - Senti Biosciences, Inc. announced participation in a Virtual Investor CEO Connect Segment, highlighting its advancements in cell and gene therapies using the Gene Circuit platform [2][3] Group 1: FDA Designation and Clinical Trials - The FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to SENTI-202, a potential first-in-class CAR-NK investigational cell therapy for relapsed/refractory hematologic malignancies, including AML [3] - SENTI-202 previously received Orphan Drug Designation from the FDA in June [3] - New data from a multinational clinical trial involving 20 patients (18 with evaluable responses) for SENTI-202 was presented at the American Society of Hematology (ASH) Annual Meeting [3] Group 2: Company Overview and Technology - Senti Bio is focused on developing next-generation cell and gene therapies for incurable diseases, utilizing a synthetic biology platform to engineer Gene Circuits [4] - The Gene Circuits are designed to selectively kill cancer cells while sparing healthy cells, enhancing specificity to target tissues, and allowing for post-administration control [4] - The company's pipeline includes cell therapies targeting both liquid and solid tumors, with preclinical evidence supporting the efficacy of Gene Circuits in NK and T cells [4]

Core Viewpoint - A class action lawsuit has been filed against Skye Bioscience, Inc. for allegedly misleading investors regarding the efficacy of its lead product candidate, nimacimab, during the specified Class Period [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who acquired Skye securities from November 4, 2024, to October 3, 2025 [1][2]. - Investors have until January 16, 2026, to seek appointment as lead plaintiff representatives [2]. Group 2: Company Background - Skye Bioscience, Inc. is a clinical-stage biotechnology company based in San Diego, focusing on treatments for obesity and metabolic diseases [2]. Group 3: Allegations - The complaint claims that Skye failed to disclose that the efficacy of nimacimab was lower than previously represented, leading to an overstatement of the drug's clinical and commercial potential [3]. Group 4: Stock Impact - Following the announcement on October 6, 2025, that the primary endpoint of the Phase 2a study was not met, Skye's stock price fell by $2.85 per share, a decline of 60%, closing at $1.90 [4].

Core Insights - Oragenics, Inc. will present at the Sequire Investor Summit 2026, scheduled for January 20th-22nd, 2026, in San Juan, Puerto Rico [1] - The company aims to address the unmet medical need in concussion and mild traumatic brain injury with its lead candidate, ONP-002, which is advancing to Phase 2a clinical studies [2][3] Company Overview - Oragenics, Inc. is a clinical-stage biotechnology company focused on developing brain-targeted therapeutics using proprietary intranasal delivery technology [3] - The lead candidate, ONP-002, is being developed as a potential first-in-class treatment for concussion and mild traumatic brain injury, with ongoing Phase 2a trials in Australia and planned Phase IIb trials in the U.S. [3] - The intranasal delivery platform has potential applications for various neurological conditions, including Parkinson's disease, Alzheimer's disease, PTSD, and anxiety disorders [3] Industry Context - Puerto Rico is an attractive location for investors due to its favorable tax benefits, making it home to many family offices and wealthy investors [2]

Core Viewpoint - Kraig Biocraft Laboratories is set to deliver its first commercial spider silk fiber samples, marking a significant milestone in the commercialization of this innovative material and the beginning of competition in the spider silk market [1][5][7]. Group 1: Commercialization and Market Readiness - The upcoming deliveries represent the culmination of nearly two decades of research and development, transitioning from laboratory breakthroughs to full-scale production in Asia [2]. - These shipments are significant as they indicate that recombinant spider silk is ready for market-scale testing, paving the way for commercial revenue for the company [5]. - The ability to deliver large sample volumes is crucial for fiber and fabric evaluation, allowing for real-world performance validation before mass adoption [6]. Group 2: Competitive Advantage and Industry Impact - Kraig Labs is positioned to capture early-mover advantage in the eco-luxury apparel sector, where sustainability mandates are becoming increasingly important for brands [3]. - The company's technology combines genetic engineering with traditional sericulture, producing high-performance, biodegradable spider silk that can outperform conventional fibers [11]. - The deliveries will not only serve the fashion and performance textiles sectors but also open opportunities in luxury fashion, outdoor gear, and defense applications [10]. Group 3: Environmental Considerations - Spider silk's plastic-free profile addresses the microplastic crisis in the sustainable fashion market, which is valued at $6.5 billion, with textiles contributing to 35% of ocean pollution [4]. - The production system based on genetically engineered silkworms offers a scalable and cost-effective alternative to fermentation-based methods, enhancing sustainability in textile production [8].

Group 1 - BriaCell Therapeutics Corp. announced a public offering of 5.367 million units priced at $5.59 per unit, aiming for gross proceeds of approximately $30 million [1] - Each unit consists of one common share and one warrant, with the warrant exercisable at $6.93 per share and expiring five years from issuance [1] - Following the announcement, the stock price dropped 54.12% to $5.01 [2] Group 2 - The warrants have been approved for listing on the Nasdaq Capital Market under the symbol "BCTXL," expected to begin trading on January 14, 2026 [2] - The offering is anticipated to close on January 15, 2026 [2] - The company plans to use the net proceeds for working capital and general corporate purposes [3] Group 3 - BriaCell recently reported a sustained complete resolution of lung metastasis in a breast cancer patient treated with its Bria-OTS personalized immunotherapy, boosting stock prices to $12.10 [3] - Over 11 months, the treatment response was confirmed without treatment-limiting toxicities, enhancing confidence in the Bria-OTS platform [4] - The stock traded between $3.00 and $98.20 over the past year, closing at $10.92, up 43.12% prior to the offering announcement [4]

Core Viewpoint - Genmab is transitioning from a royalty-based company to a fully integrated, innovation-driven biotech firm with a focus on proprietary medicines and a robust late-stage pipeline, positioning itself for sustainable long-term growth into the 2030s [2][3]. Group 1: Company Overview - Genmab has evolved over the past decade, enhancing its portfolio and capabilities [2]. - The company is now characterized by a diversified revenue base and three high-impact late-stage programs [2]. Group 2: Growth Strategy - The company aims to leverage its high-quality revenue base and late-stage portfolio to drive sustainable growth well into the next decade [3].

Group 1 - The presentation is part of the 44th Annual Healthcare Conference hosted by JPMorgan [1] - BioNTech's CEO, Ugur Sahin, is set to present and participate in a Q&A session [2]

Core Viewpoint - Zai Lab emphasizes the importance of both its China business and global portfolio, indicating a strategic dual-engine approach to growth and innovation [2][3]. Group 1: Company Overview - Zai Lab was founded 11 years ago with a dual focus on commercial opportunities in China and a global portfolio for innovation [3]. - The company has successfully obtained approval for 8 products in China, projecting sales of approximately $460 million [4]. Group 2: Strategic Focus - The company aims to serve as a partner for global biotech firms lacking capabilities in China while also promoting Chinese innovations globally [3]. - The commercial engine of Zai Lab is designed to accelerate growth, reflecting a strategic emphasis on both local and international markets [3].

Beam Therapeutics Conference Call Summary Company Overview - **Company**: Beam Therapeutics (NasdaqGS:BEAM) - **Industry**: Biotechnology, specifically gene editing for rare and common disorders Key Points and Arguments Vision and Technology - Beam Therapeutics aims to provide lifelong cures for patients with serious diseases through gene editing, focusing on one-time curative therapies with lasting effects [2][4] - The company utilizes base editing technology, which allows precise single-letter changes in genes without creating double-stranded breaks, leading to predictable and durable outcomes [4][5] Recent Achievements - In 2024, Beam presented significant data on base editing for severe sickle cell disease, demonstrating dramatic results [2][3] - The first data for base editing in alpha-1 antitrypsin deficiency (Beam 302) was published, showcasing the ability to rewrite a broken gene back to normal [3][12] Clinical Programs - **Beam 302**: Aimed at correcting the single-letter misspelling in the SERPINA1 gene responsible for alpha-1 antitrypsin deficiency, with the goal of restoring normal protein levels and addressing both lung and liver issues [15][16] - **Ristacel**: Targeting sickle cell disease, with a focus on achieving deeper resolution of the disease and improving patient outcomes [22][23] Regulatory Progress - Beam has received RMAT designation from the FDA, allowing for accelerated approval pathways for its therapies [18][19] - The company anticipates submitting a Biologics License Application (BLA) for Ristacel by the end of 2026 [29] Financial Position - Beam reported having $1.25 billion in cash at the end of the year, providing a runway into 2029 for the development and commercialization of its therapies [10][11] Market Potential - The company believes that its therapies will reduce lifetime healthcare costs and improve patient outcomes, making them attractive to payers [7][8] - There is significant patient interest and a growing number of treatment centers prepared to administer Beam's therapies [25][27] Future Directions - Beam plans to expand its pipeline with additional liver-targeted genetic disease programs and continue advancing its hematology franchise [33][34] - The company is also focusing on in vivo delivery methods to enhance scalability and reach more patients [30][31] Additional Important Information - Beam's base editing technology is adaptable and scalable, with a strong emphasis on manufacturing efficiency [9][43] - The company has established partnerships that have generated over $900 million in non-dilutive funding, enhancing its research capabilities [32] - Beam is committed to addressing unmet medical needs in rare diseases, with a focus on both therapeutic impact and commercial viability [56] This summary encapsulates the key points discussed during the conference call, highlighting Beam Therapeutics' innovative approach to gene editing, recent achievements, regulatory progress, financial strength, and future plans in the biotechnology sector.